PortalPublikationenStudien und personalisierte Medizin in der Onkologie?

Studien und personalisierte Medizin in der Onkologie?

Standard

Studien und personalisierte Medizin in der Onkologie? / Arnold, Dirk; Bokemeyer, Carsten.

in: ONKOLOGIE, Jahrgang 33, Nr. 7, 7, 01.01.2010, S. 25-29.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Arnold, D & Bokemeyer, C 2010, 'Studien und personalisierte Medizin in der Onkologie?', ONKOLOGIE, Jg. 33, Nr. 7, 7, S. 25-29. https://doi.org/10.1159/000319739

APA

Arnold, D., & Bokemeyer, C. (2010). Studien und personalisierte Medizin in der Onkologie? ONKOLOGIE, 33(7), 25-29. [7]. https://doi.org/10.1159/000319739

Vancouver

Arnold D, Bokemeyer C. Studien und personalisierte Medizin in der Onkologie? ONKOLOGIE. 2010 Jan 1;33(7):25-29. 7. https://doi.org/10.1159/000319739

Bibtex

@article{5293ec9bb2fd4d908f7922cc796e94b5,
title = "Studien und personalisierte Medizin in der Onkologie?",
abstract = "Clinical trials aim to evaluate benefits of therapeutic or diagnostic procedures for a 'standardized' cohort rather than for individual patients. On the other hand, 'personalized medicine' focuses on the prediction of potential benefits or risks for individuals in as much detail as possible.Currently, clinical trials may still implement the known predictive and/or prognostic factors, as they generally address relatively large groups of patients bearing a well-identified factor and therefore defining an 'enriched' patient cohort. In the near future, as more and more factors for stratification will become available,it is likely that patient cohorts become smaller--hopefully with an increase in the observed effect. Therefore, innovative designs of clinical trials are warranted to integrate the needs of better stratification in smaller patient subsets.",
keywords = "Biomedical Research, Germany, Humans, Individualized Medicine, Medical Oncology, Neoplasms",
author = "Dirk Arnold and Carsten Bokemeyer",
note = "Copyright {\textcopyright} 2010 S. Karger AG, Basel.",
year = "2010",
month = jan,
day = "1",
doi = "10.1159/000319739",
language = "Deutsch",
volume = "33",
pages = "25--29",
journal = "ONKOLOGIE",
issn = "0378-584X",
publisher = "S. Karger AG",
number = "7",

}

RIS

TY - JOUR

T1 - Studien und personalisierte Medizin in der Onkologie?

AU - Arnold, Dirk

AU - Bokemeyer, Carsten

N1 - Copyright © 2010 S. Karger AG, Basel.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Clinical trials aim to evaluate benefits of therapeutic or diagnostic procedures for a 'standardized' cohort rather than for individual patients. On the other hand, 'personalized medicine' focuses on the prediction of potential benefits or risks for individuals in as much detail as possible.Currently, clinical trials may still implement the known predictive and/or prognostic factors, as they generally address relatively large groups of patients bearing a well-identified factor and therefore defining an 'enriched' patient cohort. In the near future, as more and more factors for stratification will become available,it is likely that patient cohorts become smaller--hopefully with an increase in the observed effect. Therefore, innovative designs of clinical trials are warranted to integrate the needs of better stratification in smaller patient subsets.

AB - Clinical trials aim to evaluate benefits of therapeutic or diagnostic procedures for a 'standardized' cohort rather than for individual patients. On the other hand, 'personalized medicine' focuses on the prediction of potential benefits or risks for individuals in as much detail as possible.Currently, clinical trials may still implement the known predictive and/or prognostic factors, as they generally address relatively large groups of patients bearing a well-identified factor and therefore defining an 'enriched' patient cohort. In the near future, as more and more factors for stratification will become available,it is likely that patient cohorts become smaller--hopefully with an increase in the observed effect. Therefore, innovative designs of clinical trials are warranted to integrate the needs of better stratification in smaller patient subsets.

KW - Biomedical Research

KW - Germany

KW - Humans

KW - Individualized Medicine

KW - Medical Oncology

KW - Neoplasms

U2 - 10.1159/000319739

DO - 10.1159/000319739

M3 - SCORING: Zeitschriftenaufsatz

C2 - 20926911

VL - 33

SP - 25

EP - 29

JO - ONKOLOGIE

JF - ONKOLOGIE

SN - 0378-584X

IS - 7

M1 - 7

ER -